Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
zinacef stungulyfs-/innrennslisstofn, lausn 1,5 g
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 1,5 g
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
zinacef stungulyfs-/innrennslisstofn, lausn 750 mg
sandoz a/s - cefuroximum natríum - stungulyfs-/innrennslisstofn, lausn - 750 mg
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
eligard stungulyfsstofn og leysir, lausn 7,5 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 7,5 mg
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
eligard stungulyfsstofn og leysir, lausn 45 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 45 mg
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
eligard stungulyfsstofn og leysir, lausn 22,5 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 22,5 mg
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
ivomec vet. stungulyf, lausn 10 mg/ml
boehringer ingelheim animal health france scs - ivermectinum inn - stungulyf, lausn - 10 mg/ml
Իսլանդիա -
իսլանդերեն -
LYFJASTOFNUN (Icelandic Medicines Agency)
noromectin stungulyf, lausn 1 % w/v
norbrook laboratories (ireland) limited - ivermectinum inn - stungulyf, lausn - 1 % w/v
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
truscient
zoetis belgium sa - dibotermin alfa - beinmyndunarprótein - hundar - osteoinductive agent til notkunar við meðferð á beinbrotum í beinum sem viðbót við hefðbundna skurðaðgerð með því að nota opinn brot á beinbrotum hjá hundum.
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
solensia
zoetis belgium sa - frunevetmab - verkjalyf - kettir - for the alleviation of pain associated with osteoarthritis in cats.
Եվրոպական Միություն -
իսլանդերեն -
EMA (European Medicines Agency)
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.